Pasireotide (SOM230) is Effective for the Treatment of Pancreatic Neuroendocrine Tumors (PNETs) in a Multiple Endocrine Neoplasia Type 1 (MEN1) Conditional Knockout Mouse Model

BACKGROUND: Pasireotide (SOM230), a long acting somatostatin analogue (LAR) has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, glucose levels, tumor growth, and survival using an MEN1 transgenic mouse model. METHODS: Eight 12 month-old condi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Quinn, Thomas J., Yuan, Ziqiang, Adem, Asha, Geha, Rula, Vrikshajanani, Chakravarthy, Koba, Wade, Fine, Eugene, Hughes, David T., Schmid, Herbert, Libutti, Steven K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732168/
https://ncbi.nlm.nih.gov/pubmed/23102680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2012.08.021
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky